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Abstract 
The aim of the study was to investigate how the fine particle content of lactose 
carriers prepared with different types of lactose fines regulates dry powder inhaler 
(DPI) formulation performance of a cohesive batch of micronised budesonide. 
Budesonide formulations (0.8 wt-% ) were prepared with three different lactose 
carriers (Lactohale (LH) LH100, 20 wt-% LH210 in LH100 and 20 wt-% LH300 in 
LH100). Fine particle fraction of emitted dose (FPFED) and mean mass aerodynamic 
diameter (MMAD) of budesonide was assessed with a Next Generation Impactor 
(NGI) using a Cyclohaler at 90 l/min. Morphological and chemical characteristics of 
particles deposited on Stage 2 were determined using a Malvern Morphologi G3-ID. 
The results indicate that increasing concentration of lactose fines (<4.5 µm) not only 
increased the FPFED but also the MMAD of budesonide, suggesting drug deposition 
in agglomerates. Presence of agglomerates on Stage 2 was confirmed by 
morphological analysis of particles. Raman analysis of material collected on Stage 2 
indicated that the more fine lactose particles were available the more agglomerates 
of budesonide and lactose were delivered to the Stage 2. These results suggest 
drug-fines agglomerate formation is an important mechanism for how lactose fines 
improve and regulate DPI formulation performance. 
 
Keywords: Lactose, dry powder inhaler, Raman spectroscopy 
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1. Introduction 
In dry powder inhaler (DPI) formulations, drug particles with aerodynamic diameters 
of less than 5 µm are required to target the conducting airways. The particle size is 
conventionally achieved by secondary processing of crystalline drug using energy 
intensive air-jet micronisation (Chan, 2006). However, due to the high interparticle 
forces in micronised, cohesive Geldart type C (Geldart, 1973) powders, and low 
doses required for drug delivery to the lungs, metering of and fluidising a drug only 
dose is onerous. Thus, to allow adequate metering and increased flowability of the 
powder, the micronised drug is commonly formulated with coarser, fluidisable 
Geldart type A (Geldart, 1973) carrier particles. The carrier of choice for DPI 
formulations is most often alpha lactose monohydrate.  
 
Historically, a vast number of studies, reviewed by Jones and Price (2006), have 
shown that the presence of fine lactose particles in a DPI formulation improves the 
formulation performance in terms of delivered dose. As a general rule, therefore, in 
addition to the drug and the coarse carrier, fine particle lactose is often present in 
DPI formulations, either as an extrinsic added fraction of fines or as intrinsic fines 
within the coarse carrier. However, to date, the exact mechanism for how these fine 
lactose particles alter the formulation performance has remained unclear, with active 
sites (El-Sabawi et al., 2006; Ganderton, 1992; Young et al., 2005), drug-lactose fine 
agglomerate formation (Lucas et al., 1998), and increased cohesion (Shur et al., 
2008) theories attempting to explain the phenomenon. Due to the shortcomings of 
each of these theories, more recently it has also been suggested that all these three 
theories may be at play simultaneously (Grasmeijer et al., 2014). The concept of 
total fines, which also takes the concentration of the drug in the formulation into 
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account when defining fines, has also been introduced as an explanation for the 
improved performance in the presence of a fine particle component (Thalberg et al., 
2012). It has also been suggested that a more favourable powder microstructure for 
deagglomeration may be achieved by adding lactose fines (Behara et al., 2011). 
 
As required by the regulatory authorities, cascade impactors are routinely used for 
assessing the DPI formulation performance (European Medicines Agency, 2007). 
Traditionally, the drug content in the different parts of the impactor is assayed by 
solution chemistry based techniques. However, some studies have also made an 
attempt of understanding the mechanisms by which the lactose fines govern the DPI 
performance by determining the deposition of lactose in the different parts of the 
impactor alongside the drug determination (Guchardi et al., 2008; Karhu et al., 2000; 
Srichana et al., 1998b). These studies proved that in addition to the drug, also fine 
lactose is deposited on the impactor stages. However, due to the limitations of the 
traditional solution chemistry based analytical techniques, these studies only 
provided speculative evidence of agglomerate formation between the lactose fines 
and the drug. Therefore, to study the possible co-deposition of the drug and lactose 
fines, there remains a need for discovering novel characterisation methods to probe 
the possible interactions between the lactose fines and drug particles upon 
deposition.  
 
Combination of the scanning electron microscopy and X-ray microanalysis has been 
used for studying the interactions between lactose and salbutamol sulphate particles 
(Srichana et al. 1998a). More recently, Raman spectroscopy has emerged as a 
promising technique for studying particulate interactions especially in combination 
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pressurised metered dose (pMDI) formulations (Rogueda et al., 2011; Steele et al., 
2004; Theophilus et al., 2006). However, also studies where DPI products have been 
investigated using Raman spectroscopy have been published (Kinnunen et al. 2009, 
Šašić and Harding, 2010). Both the studies concluded that Raman spectroscopy was 
a promising technique for studying deposition patterns of DPI formulation 
components. However, both these studies only demonstrated the capability of 
Raman spectroscopy in analysing particulate interactions taking place in DPI 
formulations and were limited in their experimental approach due to low number of 
particles analysed. Following recent developments in instrumentation, the next step 
for gaining statistically significant data was taken in the current study as 
morphologically directed Raman spectroscopy was used for characterising the 
morphological properties and chemical composition of the material delivered to the 
impactor stages in parallel with traditional in vitro performance assay of the 
formulations. 
 
The aim of the current study was to investigate the drug deposition in the Next 
Generation Impactor from DPI formulations containing different amounts and types 
of extrinsic lactose fines in greater detail using morphologically directed Raman 
spectroscopy (MDRS) in parallel with in vitro performance assessment of the 
formulations. Particular emphasis of the study was on investigating and quantifying 
the extent of possible agglomerate formation and co-deposition of lactose fines and 
a model drug, micronised budesonide, and how this influences the formulation 
performance as a whole. This was done to enhance the understanding of the 
mechanisms governing drug delivery from DPI formulations containing fine particle 
lactose.  
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2 Materials and methods 
 
2.1 Materials 
Lactohale products, namely a coarse, sieved grade of lactose Lactohale®100, 
micronised grade Lactohale®300 and a milled grade Lactohale®210 (Hereafter 
designated as LH100, LH300 and LH210, respectively), were all donated by DFE 
Pharma (Goch, Germany). Micronised budesonide with particle size within the 
respirable range (d90=4.40 µm) and a cohesive-adhesive balance (CAB) value of 
0.62 (Kinnunen et al., 2014) was received from Sterling S.r.l (Perugia, Italy). 
 
Water used during the study was reverse osmosis purified (Merck Millipore, 
Darmstadt, Germany). Acetonitrile and methanol were purchased from Sigma Aldrich 
(Gillingham, UK) and were of HPLC quality.  
 
2.2 Preparation of lactose pre-blends 
The fine grades of lactose (LH300 and LH210) were blended with the coarse grade 
of lactose (LH100) at 20 wt-% concentration. Briefly, 20 g of the fine lactose was 
sandwiched between 80 g of LH100 in two layers in a stainless steel vessel with a 
volume of 500 cm3.  The headspace within the vessel was approximately 1/3 of the 
volume of the vessel. Turbula (Glen Creston, Middlesex, UK) blending at 46 rpm was 
applied for 60 minutes after which the pre-blends were passed through 850 µm 
aperture sieve to break up any large agglomerates. The pre-blends were stored at 
20 ± 2 °C and 44% relative humidity (RH) for at least 24 hours before any further 
work was performed.  
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2.3 Particle sizing of the lactose carriers 
The particle size distributions of the lactose carriers were characterised using a 
Sympatec Helos laser diffraction system equipped with R4 lens and controlled by 
Windox X software (both from Sympatec, Clausthal-Zellerfield, Germany). The Helos 
dry dispersion system with the disperser pressure set to 2 bar was used for 
introducing the powder into the measurement zone in conjunction with Vibri powder 
feeder with a feed rate of 30% and gap width of 2 mm. The background scattering 
was recorded for 10 seconds after which five repeated measurements of 5 seconds 
duration were recorded for each of the samples with the optical concentration 
threshold set to 0.5%.  High resolution laser diffraction (HRLD) model of the Windox 
software was used for converting the raw scattering data into particle size 
distributions. 
 
2.4 Preparation of model DPI formulations 
Model DPI formulations were prepared with micronised budesonide at 0.8 wt-% 
concentration in quantities of 40 g. The CAB value of the budesonide (0.62) meant 
that the drug is adhesive to the lactose and therefore low shear Turbula blending 
could be used for obtaining a uniform blend between the lactose carrier and the drug 
particles. Briefly, budesonide was sandwiched between half of the lactose and 
blended with a Turbula in a stainless steel vessel of 500 cm3 volume for 10 minutes 
at 46 rpm. The remaining lactose was then added and further 45 minutes of blending 
was applied. The blends were subsequently passed through a 250 µm aperture 
sieve and stored at 20 ± 2 °C and 44% RH for at least 24 hours before any further 
work was carried out. To ensure that the dose variation was below 6%, the content 
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uniformity of the blends was assessed by taking ten aliquots of 12.5 mg from 
different parts of the formulation and assaying the drug content within the aliquots.  
 
2.5 In vitro assessment of formulation performance  
Size 3 hydroxypropylmethylcellulose (HPMC) capsules (Qualicaps, Spain) were 
manually filled with 12.5 mg of the formulations. A Cyclohaler device (Teva 
Pharmaceuticals, The Netherlands) was used for aerosolising the formulations into a 
Next Generation Impactor (NGI, Copley Scientific, Nottingham, UK) equipped with a 
pre-separator. Air was drawn through the impactor at 90 l/min for 2.7 seconds 
(Kubavat et al., 2012) as controlled by a TPK critical flow controller (also from Copley 
Scientific). Two capsules were aerosolised into the impactor with plates coated with 
silicone oil and the pre-separator filled with 15 ml of mobile phase. The drug 
collected in the different parts of the impactor was dissolved in mobile phase and the 
drug content assayed by high performance liquid chromatography (HPLC). 
 
The mean mass aerodynamic diameter (MMAD) and fine particle fraction (<5 µm) of 
budesonide were calculated from the cumulative impactor stage-by-stage deposition 
data as instructed by the Pharmacopoeia (EMA, 2007). The fine particle fraction of 
emitted dose (FPFED) is defined as the ratio between the fine particle mass and the 
dose of the drug recovered after the capsule and device.   
 
2.6 High performance chromatography (HPLC) assay of budesonide 
The concentration of budesonide collected in the different parts of the impactor was 
assessed using high performance liquid chromatography (HPLC) following a method 
reported elsewhere (Kubavat et al., 2012). Briefly, the samples were dissolved in 
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mobile phase consisting of 20% water, 35% acetonitrile and 45% methanol. The flow 
rate through the HPLC system was set to 1.5 ml/min using a PU-980 pump (Jasco, 
Tokyo, Japan). Aliquots of 100 µl of volume were injected into a 250 mm long 
Hypersil-ODS column with an inner diameter of 4.6mm and packing material particle 
size of 5 µm (Thermo Scientific, Loughborough, UK) using an AS-950 autosampler 
(Jasco, Tokyo, Japan). The column oven CO-965 (Jasco, Tokyo, Japan) 
temperature was set to 40°C  and wavelength of 244 nm was used for detecting 
budesonide on a UV-975 detector (Jasco, Tokyo, Japan). The peak eluted at 3.75 
min. 
 
2.7 Morphological and chemical characterisation of material deposited in the 
Next Generation Impactor  
A mirror surfaced microscope slide was placed underneath the nozzles on Stage 2 of 
the NGI to collect sample of deposited material from each of the formulations under 
investigation. The morphological properties of the collected particles were 
characterised on the Morphologi G3-ID morphologically directed Raman system 
(Malvern Instruments, Worcestershire, UK). Episcopic bright field illumination was 
used for the microscopic visualisation of the particles with the light intensity 
calibrated to 80.0 ± 0.2 %. The samples were scanned using the 50x objective lens 
with the focus fixed at 0 µm and the plate tilt compensation enabled. The scan area 
size was set to 4.5 mm by 4.5 mm, the overlap between any two adjacent frames to 
40%, the binary threshold to a grayscale value of 130 and the trash size to 10 pixels. 
Post analysis, any touching particles were removed by filtering out particles with 
values of solidities below 0.92. Before the shape analysis, particles consisting of less 
than 100 pixels were filtered out to remove noise from the shape distributions.   
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After the morphological analysis of particles deposited on Stage 2, the particles were 
sorted according to their size using circular equivalent (CE) diameter. All the 
particles larger than 3 µm were highlighted for the Raman analysis that was 
performed using the Kaiser Optical Systems MK II Probe head integrated in the 
Morphologi G3-ID system. The XY coordinates of the particles recorded during 
the morphological analysis were used for locating the centre of mass the particles, 
where the Raman spectrum was acquired. The Raman spectrum for each of the 
particles was collected using 10 seconds exposure time with excitation at a 
wavelength of 785 nm over the spectral range of 100 to 1825 cm-1 at a resolution of 
4 cm-1. The signal was detected using a charge coupled device (CCD) camera. The 
Raman spot size with the 50x objective was approximately 3 µm in diameter. 
 
Reference Raman spectra, which were used for identifying the chemical composition 
of the material collected on Stage 2, were recorded for pure lactose and pure 
budesonide. The identification was performed by comparing the entire spectrum for 
each of the analysed particles to the library spectra of lactose and budesonide using 
the Morphologi G3-ID software by allocating matching scores for lactose and 
budesonide for the particles analysed with regards to the similarity of the spectra to 
the library spectra of lactose and budesonide. Matching score of 1 indicates identical 
spectra and score of 0 indicates the spectrum bears no resemblance to the library 
spectra at all. On the basis of the scores, the particles were classified as pure 
lactose (Lactose ≥ 0.75 and budesonide < 0.45), pure budesonide (Budesonide ≥ 
0.75 and lactose < 0.45) or an agglomerate of lactose and budesonide (All the 
remaining particles). When allocating the classification parameters for the pure 
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substances, visual comparison of the library spectra and the spectra of the particles 
was used for confirming that no obvious signals of the other component were seen in 
the spectra. Similarly, for the particles classified as agglomerates, it was visually 
inspected that the characteristic signals for both the pure substances were present in 
the spectra. 
 
3 Results and discussion 
 
3.1 Particle size of the carriers  
The fines content (%<4.5 µm) of the lactose carriers investigated in the current 
study are summarised in Table I. The proportion of fine particle lactose in the 
carriers (%<4.5 µm) increased from 1.3% for the LH100 only to 6% for the 20% 
LH210 blend and 23% for the 20% LH300 blend.  
 
3.2 In vitro performance of the formulations 
Table I illustrates that the fine particle fraction of emitted dose (FPFED) for the 
formulations increased from approximately 24 to 26 to 40% for LH100, 20 wt-% 
LH210 blend and 20% LH300 blend, correspondingly. This is in an agreement 
with previous studies (Guenette et al., 2009; Louey et al., 2003) where it was 
shown that an increase in the proportion of fine lactose particles present in the 
carrier improved the DPI formulation performance. Notably, Table I shows that 
simultaneously with improving FPFED, the mean mass aerodynamic diameter 
(MMAD) of budesonide also increased. The increase in the MMAD indicated that 
the drug was delivered to the impactor stages in larger entities upon the increase 
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in the lactose fines content. These could either be agglomerated drug particles or 
agglomerates of the fine lactose and the drug particles.   
 
The stage-by-stage deposition profiles of the drug aerosolised from the different 
formulations are presented in Figure 1. The amount of drug retained in the capsules 
was lower for the 20% LH300 formulation than for the LH100 only and 20% LH210 
formulations but the device deposition remained somewhat constant for the three 
different formulations. An increase in the mouthpiece and throat deposition was 
observed upon increasing the lactose fines content of the formulations (LH100 < 
20% LH210 blend < 20% LH300 blend). The pre-separator deposition drastically 
decreased upon increasing the fines content of the carrier, and the decrease here 
was reflected in the amount of drug delivered to the impactor stages, which generally 
speaking increased upon the increase in the fines concentration. The increase was 
significant (p<0.05) on all the stages for LH300 formulation and on stages 1 and 2 for 
LH210 formulation compared to the formulation containing LH100 only. These data 
are in an agreement with numerous previous studies where it has been shown that 
the increasing lactose fines content of a carrier results in decreased pre-separator 
deposition and increased drug delivery to the impactor stages (Louey et al., 2003; 
Louey and Stewart, 2002; Srichana et al., 1998b; Steckel et al., 2006).  
 
3.3 Morphological and chemical characteristics of material deposited on 
Stage 2 
The number based and volume converted circular equivalent (CE) diameter 
distributions of the material collected on the NGI Stage 2 from the different 
formulations are summarised in Table II. In number terms, a slight increase in the 
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value of d10 from 1.56 to 1.86 µm was seen as the fines content of the formulations 
was increased. The cut-off diameter of Stage 2 when the NGI is operated at 90 l/min 
is 3.61 µm (Marple et al., 2003). Table II shows that the number based values of d50 
measured for the formulations were close to this at 3.62 to 3.94 µm. Values of d50 
did not exhibit a clear trend related to the fines content of the formulations. In terms 
of d90, an increase from 5.77 to 6.72 µm was apparent as the fines content 
increased. The increasing particle size in the upper end of the distributions as the 
fines content was increased is clearly visible in Figure 2A, where the number based 
CE diameter distributions of the material collected on Stage 2 from the different 
formulations are presented. Table II and Figure 2B, where the volume converted CE 
diameter distributions of the material collected on Stage 2 are shown, indicate that in 
volume terms, the increase in the particle size at the upper end of the distributions 
was even more pronounced  with d90 increasing from 8.06 to 10.4 µm. These data 
suggest the material collected on Stage 2 became increasingly agglomerated upon 
increasing lactose fines content of the formulation.  
 
Particle shape of the material collected from Stage 2 is summarised in Table II in 
terms of mean high sensitivity (HS) circularity and convexity values for the different 
formulations. In case of both the shape descriptors, a decreasing trend in the mean 
values was seen as the lactose fines concentration of the formulations was 
increased. Following the definition of these shape parameters (Willen, 2008), the 
higher the value of the parameters, the more compact the shape of a particle. It is 
also known that agglomerates often exhibit less compact shape than primary 
particles (Huck, 2007). Therefore, the decreasing trend in the particle shape 
descriptors upon the addition of fines indicated an increased presence of 
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agglomerates. The increasing degree of agglomeration in the presence of lactose 
fines, as indicated by the larger particle size and less compact shape, is in an 
agreement with the increase observed in MMAD of the drug aerosolised from the 
formulations upon addition of the fines, as was shown in Table I, and coincide with 
improved formulation performance. Therefore, these data suggest that agglomerate 
formation and/or co-deposition play an important role in increasing DPI formulation 
performance. 
 
To further investigate the possible agglomerate formation and co-deposition between 
budesonide and lactose fines, a novel approach of Raman analysis of significant 
number of particles collected on Stage 2 was taken. A 50x magnification field of view 
photomicrograph of material deposited on Stage 2 from the 20% LH300 formulation 
is presented in Figure 3. The photomicrograph clearly demonstrates that both 
primary and agglomerated particles were collected on Stage 2. The Raman 
spectroscopic characterisation enabled the analysis of the chemical components 
forming these agglomerates. The Raman spectrum of the highlighted particle is 
displayed on the top right of Figure 3 and the library spectra of lactose and 
budesonide below that. The characteristic, strong signal of budesonide at 1656 cm-1, 
deriving from the stretching vibration of C=C bond in the aromatic ring of the steroid 
backbone of the molecule (Ali et al., 2007), is present in the spectrum of the 
highlighted particle. Also the fingerprint for the glycosidic bond of lactose between 
the wavelengths of 300 and 500 cm-1 (Susi and Ard, 1974) is exhibited in the 
spectrum of the highlighted particle. The matching scores for the library spectra as 
allocated by the Morphologi G3-ID software for this particle were 0.681 for lactose 
and 0.635 for budesonide. Therefore, based on the matching scores and the visual 
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inspection of the Raman spectrum, the highlighted particle could be identified as an 
agglomerate of lactose and budesonide. Similarly, primary particles of lactose and 
budesonide could be characterised based on their Raman spectrum. This way, the 
chemical composition of 1353 (LH100), 1095 (+20% LH210) and 1156 (+20% 
LH300) particles collected on Stage 2 were characterised for the formulations. 
 
Following the Raman spectroscopic fingerprinting of the particles collected on Stage 
2, a classification was set up according to whether the material was lactose, 
budesonide or an agglomerate of the two components. Proportions of the different 
chemical species in the different formulations are summarised in Table III. These 
data show that, even for the formulation prepared with LH100 only, nearly 40% of the 
particles delivered to the impactor Stage 2 were lactose. With added lactose fines, 
the proportion of lactose delivered to the Stage 2 was even higher at approximately 
80%. These data are in an agreement with previous studies, where it was reported 
that fine particle lactose is indeed delivered to the impactor stages (Guchardi et al., 
2008; Karhu et al., 2000; Srichana et al., 1998b).   
 
Table III also demonstrates that the majority, nearly half, of the particles on Stage 2 
from the LH100 only formulation were budesonide. In contrast, the proportion of pure 
budesonide in the formulations with added lactose fines was very low, with 10% for 
the 20% LH210 formulation and 6% for the 20% LH300 formulation characterised as 
pure budesonide.  
 
Analysing the amounts of lactose and the drug particles delivered to the different 
parts of the impactor is straightforward by different chemical assays, and indeed has 
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been carried out in previous studies (Srichana et al., 1998a). However, while 
providing valuable information on co-deposition, these techniques cannot be used for 
addressing the possible presence of drug-lactose fine agglomerates. Using Raman 
spectroscopy for analysing the chemical composition of the particles collected on the 
impactor stages enables studying the possible agglomerate formation between two 
chemically different species. A previous study used Raman spectroscopy for 
qualitatively assessing the chemical composition of material deposited on the 
impactor stages (Kinnunen et al., 2009). The results showed co-deposition of lactose 
and drug took place. The next step was taken in the current study by quantifying the 
proportions of drug-lactose agglomerates delivered to the impactor stage. Table III 
demonstrates that, of all the particles deposited on Stage 2, the proportion of 
agglomerates of budesonide and lactose fines remained somewhat constant for all 
the formulations with the proportion varying between 11.5 and 17.0%.  
 
To understand the underlying mechanisms for how the lactose fines alter the DPI 
performance, further analysis relating the in vitro deposition of the drug to the 
proportion of drug delivered to Stage 2 either as pure budesonide or agglomerates 
was performed. These data are summarised in Table IV. The total proportion of 
budesonide containing species (pure budesonide and agglomerates) was 
approximately 63% for the LH100 only formulation and approximately 20% for the 
formulations containing added lactose fines. Because the proportions of 
agglomerates and pure budesonide of the budesonide containing species were 
known (Table III), the amounts of budesonide in agglomerates and as pure 
budesonide could be quantified. This analysis revealed that interestingly, as shown 
in Table IV, the mass of the drug delivered on the Stage 2 of the impactor as pure 
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budesonide remained somewhat constant at between 2.2 and 2.6 µg from all the 
formulations. Meanwhile, the mass of budesonide delivered to the Stage 2 as 
agglomerates increased from 0.7 to 2.6 to 7.4 µg, respectively, as the lactose fines 
content of the formulations increased. For 20% LH210 formulation the mass of 
budesonide in agglomerates was approximately four times as high as for LH100 
formulation. For 20% LH300 formulation, the mass of budesonide in agglomerates 
on Stage 2 was tenfold compared to the LH100 only formulation. Figure 4 clearly 
illustrates the increasing trend in the proportion of budesonide deposited as 
agglomerates with a decrease in the proportion of pure budesonide upon increasing 
lactose fines content of the carrier.  
 
These data therefore demonstrate that agglomerate formation and co-deposition of 
lactose fines and a cohesive batch of micronised budesonide takes place upon the 
addition of lactose fines and consequentially, an improvement in the DPI 
performance is achieved. These results also indicate that the lactose fines have to 
be fine enough to be co-deposited in the impactor stages with the drug if an 
improvement in formulation performance is to be gained. Therefore, these results 
also explain why only the finest fractions of lactose fines are efficient in improving the 
DPI performance, as has been previously reported (Guenette et al., 2009; Louey et 
al., 2003) 
 
4 Conclusions 
A combination of in vitro testing, morphological analysis and Raman spectroscopy 
was used to investigate the mechanisms that govern fine particle deposition in 
carrier based DPIs. The in vitro analysis established an improvement in the fine 
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particle delivery and an increasing trend in MMAD upon increasing concentration of 
lactose fines present in the carrier. Morphological analysis of material deposited on 
Stage 2 demonstrated increasing particle size and less compact shape, both 
characteristic of agglomerate formation, upon increasing lactose fines content. By 
means of Raman spectroscopy, proportions of pure budesonide and lactose, and the 
agglomerates of the two materials delivered to Stage 2 could be quantified.  The 
amount of budesonide-only particles on stage 2 was found to be constant for all 
three formulations, and an increasing amount of budesonide upon increasing lactose 
fines was observed. This was attributed to agglomerate formation between lactose 
fines and budesonide. Therefore, the results of this study compellingly demonstrate 
that agglomerate formation between drug and the lactose fines is very likely a 
dominating mechanism for how extrinsic lactose fines improve and regulate DPI 
performance. The more fines were available within the carrier, the more budesonide 
was agglomerated with the fines, and consequentially delivered to the impactor 
stage. The results also shed light to the question why only finest lactose fines are 
efficient in improving the DPI performance. This is because the lactose fines have to 
be fine enough to be co-deposited within the impactor with the drug particles. As a 
consequence, the results of the study highlighted why the proportion of fine particles 
present in the carrier is such a popular tool for predicting the DPI performance 
amongst the formulators. 
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Tables 
Table I Average proportion of fines below 4.5 µm in the lactose carriers (%<4.5 µm, 
n=5) and summary of in vitro performance of budesonide formulations prepared with 
the carriers in terms of fine particle fraction of emitted dose (FPFED) and mean mass 
aerodynamic diameter (MMAD). The data for FPFED and MMAD represents mean ± 
standard deviation, n=3. 
 
% < 4.5 
µm 
FPFED ± 
S.D. (%) 
MMAD ± S.D. 
(µm) 
LH100 1.29 24.10 ± 0.24 2.58 ± 0.02 
+20% LH210  6.02 26.63 ± 0.13 3.14 ± 0.01  
+20% LH300 23.04 39.74 ± 1.34 3.36 ± 0.03 
 
 
Table II The 10th, 50th and 90th percentiles of number based and volume converted 
circular equivalent (CE) diameter distributions and mean values of high sensitivity 
(HS) circularity and convexity of material collected on Stage 2 of the Next Generation 
Impactor 
 
Number based 
particle size 
(µm) 
Volume converted 
particle size 
(µm) 
Particle shape 
Mean values 
d10 d50 d90 d10 d50 d90 
HS 
Circularity1 
Convexity2 
LH100 1.56 3.84 5.77 3.68 5.35 8.06 0.859 0.986 
+20% LH210 1.72 3.62 6.14 3.60 5.98 9.48 0.846 0.983 
+20% LH300 1.86 3.94 6.72 3.95 6.53 10.4 0.824 0.980 
1 Convexity is calculated as convex hull diameter of a particle divided by the 
actual perimeter of the particle 
2 High sensitivity (HS) circularity is calculated as 4π times the area of the 
particle over perimeter squared 
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Table III Proportions of budesonide, lactose and agglomerates of the two species 
deposited on Stage 2 of the Next Generation Impactor from the different formulations 
aerosolised on Cyclohaler at 90 l/min. The data are based on Raman analysis of 
1353 (LH100), 1095 (+20% LH210) and 1156 (+20% LH300) particles collected on a 
microscope slide placed on Stage 2. 
 
Lactose 
(%) 
Budesonide 
(%) 
Agglomerates 
(%) 
LH100 37.4 48.8 13.8 
+20% LH210 79.0 9.5 11.5 
+20% LH300 77.3 5.7 17.0 
 
 
Table IV The mean ± standard deviation (n=3)  amount of budesonide recovered 
from Stage 2 of the Next Generation Impactor, total proportion of species containing 
budesonide of the particles analysed by Raman for each of the formulations and the 
amount of pure budesonide and budesonide in agglomerates on Stage 2 based on 
the Raman analysis. 
 
Budesonide 
on Stage 2 ± 
S.D. (µg) 
Total 
budesonide 
(%) 
Pure 
budesonide 
(µg) 
Budesonide 
in 
agglomerates 
(µg) 
LH100 3.37 ± 0.10 
4.78 ± 0.10 
9.82 ± 0.14 
62.6 2.6 0.7 
+20% LH210 21.0 2.2 2.6 
+20% LH300 22.7 2.4 7.4 
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Figures 
 
Figure 1. Stage-by-stage deposition profile of micronised budesonide within the Next 
Generation Impactor from model formulations prepared with LH100 (black bars), 
20% LH210 in LH100 (light grey) and 20% LH300 in LH100 (dark grey) as carriers 
and aerosolised using a Cyclohaler device at 90 l/min. The error bars represent 
standard deviation, n=3. MP & T is mouthpiece and throat, PS is pre-separator and S 
denotes stage. Stages 6-8 are grouped together for clarity of presentation.  
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A) 
 
B) 
 
Figure 2. A) number based and B) volume converted circular equivalent (CE) 
diameter distributions of particles collected on a microscope slide placed on Stage 2 
of the Next Generation Impactor from formulations prepared with LH100 (solid line), 
20% LH210 in LH100 (short dash) and 20% LH300 in LH100 (long dash) as carrier 
for micronised budesonide aerosolised at 90 l/min on a Cyclohaler. 
 
Figure 3. A 50x magnification field of view photomicrograph of particles deposited on 
Stage 2 of the Next Generation Impactor (left), the Raman spectra of the highlighted 
particle (top right) and the library spectra of α-lactose monohydrate (middle right) and 
budesonide (bottom right) 
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Figure 4. Proportions of pure budesonide (black) and the agglomerates of 
budesonide and lactose (grey) of the budesonide containing species collected on 
Stage 2 of the Next Generation Impactor when aerosolised from the formulations of 
micronised budesonide with LH100 (left), 20% LH210 in LH100 (middle) and 20% 
LH300 in LH100 (right) and as characterised by the Raman fingerprint of the 
particles 
 
